 SAN DIEGO, May 10, 2021 PRNewswire -- Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application NDA resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration FDA, continues under review. 